多发性骨髓瘤患者肾功能不全的发病率、预后影响与临床结局:一项基于人群登记的研究
基于法国Gironde地区1038例新诊断多发性骨髓瘤(MM)的人群登记,24.6%患者合并肾功能不全(RI),其中12.9%需血液透析; RI患者中位生存21个月,而无RI患者3年生存未达中位(P<0.01)。观察性研究中,血液学反应与既往慢性肾脏病与肾脏反应相关,血液学反应和肾脏反应与1年总生存相关。
要点
- MM患者中24.6%合并RI,12.9%需透析,RI为独立负性预后因素。
- RI对超额死亡风险的影响在诊断后前6个月最大。
- 血液学反应和肾脏反应是与生存相关的最强标志。
核心结论
- RI是多发性骨髓瘤诊断后前6个月的独立负性预后因素。
- 肾脏恢复和血液学反应是与患者生存相关的最强标志。
研究设计与样本
- 基于法国Gironde地区1038例新诊断多发性骨髓瘤的人群登记研究。
- 采用Pohar-Perme指标和超额死亡率回归评估净生存。
- 回顾114例多发性骨髓瘤合并RI病例描述临床结局。
主要发现
- 24.6%的多发性骨髓瘤患者存在RI,12.9%需要血液透析。
- RI患者中位生存时间为21个月,其他患者3年时中位生存未达到(P<0.01)。
- 年龄>73岁、RI、合并症及未使用药物或ASCT与超额死亡风险相关。
- RI对超额死亡率的影响在诊断后前6个月最大。
- 观察性研究中位随访22.5个月;与肾脏反应相关的因素为血液学反应(OR 6.81;P<0.01)和既往慢性肾脏病(OR 0.26;P=0.04)。
临床怎么用
- 对多发性骨髓瘤患者应早期评估肾功能,识别合并RI的高危患者。
- 诊断后前6个月需密切监测肾功能与治疗反应,因RI预后影响最大。
- 治疗中应关注血液学反应和肾脏恢复,二者与生存改善相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal impairment (RI), a severe complication in multiple myeloma (MM), is considered as a poor prognostic factor. Patient survival has increased with the use of novel drugs and autologous stem-cell transplantation (ASCT). However, specific evolution of the incidence of RI in MM and its impact on prognosis remain unclear. METHODS: Using a population-based registry of 1038 newly diagnosed MM in Gironde, France, we evaluated the incidence trends of RI in MM patients and assessed net survival according to factors of interest using Pohar-Perme indicator and excess mortality rate regression. We also reviewed 114 cases of MM with RI to describe their clinical outcomes. RESULTS: In our population-based study, 24.6% of MM patients presented with RI (12.9% required haemodialysis). Median survival time was 21 months in patients with RI versus not reached at 3 years for other patients (P < 0.01). Age >73 years, RI, comorbidities and non-use of drugs or ASCT were associated with excess mortality risk. The effect of RI on excess mortality rates was maximum in the first 6 months after diagnosis. In the observational study, median follow-up time was 22.5 months; factors associated with renal response were haematologic response [odds ratio (OR) 6.81; P < 0.01] and previous chronic kidney disease (OR 0.26; P = 0.04). Factors associated with 1-year overall survival were haematological [hazard ratio (HR) 0.13; P < 0.01] and renal response (HR 0.27; P = 0.03). CONCLUSIONS: RI represents an independent negative prognostic factor in MM in the first 6 months after diagnosis. Renal recovery and haematologic response are the strongest markers associated with patient survival.
引用
- Courant M, Orazio S, Monnereau A, et al. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transplant. 2021. PMID: 31773154. doi:10.1093/ndt/gfz211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。